Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19856499 | 0.87 | GABRA1 (0.42) | GABRA1GABRB2AURKADAPK3MAP4K4 | |
| SCHEMBL293727 | 0.79 | — | — | |
| SCHEMBL293726 | 0.79 | — | — | |
| SCHEMBL7746016 | 0.79 | — | — | |
| SCHEMBL2305673 | 0.77 | TSHR (0.32) | GABRA1GABRB2AURKADAPK3MAP4K4 | |
| SCHEMBL13718969 | 0.76 | CYP2A6 (0.36) | — | |
| SCHEMBL5831736 | 0.75 | GABRA1 (0.45) | GABRA1GABRB2AURKADAPK3MAP4K4 | |
| SCHEMBL8382670 | 0.75 | IDO1 (0.35) | — | |
| SCHEMBL3477677 | 0.75 | L3MBTL1 (0.33) | KMT2A | |
| SCHEMBL663537 | 0.75 | GABRA1 (0.32) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675824-B1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | WURSTER SIEGFRIED (FI) | 2010-09-29 | — | — | EP | claimed |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2010-01-07 | — | — | US | claimed |
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | OY JUVANTIA PHARMA LTD (FI) | 2007-06-07 | — | — | US | claimed |
| JP-2007507473-A | — | — | 2007-03-29 | — | — | JP | claimed |
| EP-1675824-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | Oy Juvantia Pharma Ltd (FI) | 2006-07-05 | — | — | EP | claimed |
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | claimed |
| WO-2005033069-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | claimed |
| EP-3617758-B1 | COMPOSITION FOR FORMING OPTICAL WAVEGUIDE WHICH CONTAINS REACTIVE SILSESQUIOXANE COMPOUND | NISSAN CHEMICAL CORP (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-11333800-B2 | Optical waveguide-forming composition which contains reactive silsesquioxane compound | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200148875-A1 | OPTICAL WAVEGUIDE-FORMING COMPOSITION WHICH CONTAINS REACTIVE SILSESQUIOXANE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-3373051-B1 | COMPOSITION FOR FORMING OPTICAL WAVEGUIDE | NISSAN CHEMICAL CORP (JP) | 2020-03-11 | — | — | EP | disclosed |
| EP-3367144-B1 | MANUFACTURING METHOD FOR GI OPTICAL WAVEGUIDE | NISSAN CHEMICAL CORP (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617758-A1 | COMPOSITION FOR FORMING OPTICAL WAVEGUIDE WHICH CONTAINS REACTIVE SILSESQUIOXANE COMPOUND | Nissan Chemical Corporation (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-3367144-A1 | MANUFACTURING METHOD FOR GI OPTICAL WAVEGUIDE | Nissan Chemical Industries, Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| EP-3127929-A1 | POLYMERIZABLE COMPOSITION CONTAINING REACTIVE FLUORINATED SILICONE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170023704-A1 | POLYMERIZABLE COMPOSITION CONTAINING REACTIVE FLUORINE-CONTAINING SILICONE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-2029142-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | Choongwae Pharma Corporation (KR) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007139346-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2007-12-06 | — | — | WO | disclosed |
| EP-0428902-B1 | Silver halide color photographic materials | FUJI PHOTO FILM CO LTD (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0428902-A1 | Silver halide color photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SSTR4, SSTR1, SSTR3 | GABRA1 131/4885GABRB2 188/4885AURKA 2888/4885 |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | SSTR4, SSTR1, SSTR3 | GABRA1 131/4885GABRB2 188/4885AURKA 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.